Ethical considerations for semaglutide use in children.
This paper examines the ethical dimensions of prescribing semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) to children in the context of its expanding regulatory approvals for paediatric obesity management across several countries, including Germany, the UK, Denmark, and the United Arab Emirates. The authors explore tensions between the potential benefits of semaglutide — such as reducing cardiovascular risk and preventing obesity-related illness in children — and significant concerns including uncertainties about long-term safety, effects on child development, and unanswered efficacy questions in younger populations. The paper focuses particularly on three ethical challenges: access barriers and health equity, the risk of reinforcing weight-based stigma, and the tendency to overlook structural and social determinants of childhood obesity. The authors offer ethical recommendations for clinicians aimed at minimising harm, respecting children's autonomy, and promoting overall health. As an ethics and policy review paper, it does not present original clinical trial data, and its conclusions are based on normative argument and synthesis of existing literature rather than empirical evidence from controlled studies.
Why this grade: This is an ethical analysis and opinion review paper; it presents no original clinical or experimental data, so it does not independently contribute empirical evidence for or against semaglutide's efficacy or safety in humans.
Semaglutide, marketed as Ozempic, Wegovy and Rybelsus, has rapidly become one of the most prominent medications of recent years. Initially approved in 2021 for type 2 diabetes in adults, semaglutide is now authorised for obesity management in adults and children in several countries, including Germany, the UK, Denmark and the United Arab Emirates. Despite this broad regulatory approval, its paediatric use remains a subject of debate. Advocates highlight its potential to reduce cardiovascular risk and prevent obesity-related illness, while critics emphasise uncertainties about long-term safety, efficacy and impacts on child development.This paper examines the ethical challenges raised by prescribing semaglutide to children, focusing on access barriers, stigma and the neglect of structural determinants of obesity, and provides ethical recommendations for clinicians aimed at mitigating harm, supporting autonomy and promoting children's health.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.